Dr. Sridhar Srinivasan, MD

Dr. Srinivasan practices at Helen F Graham Cancer Center & Research Institute in Newark, Delaware.

Dr. Srinivasan's NPI, 1750598363, was assigned on May 16, 2007. Dr. Srinivasan graduated from Stanley Medical College SMC in 1996. Dr. Srinivasan holds Florida license ME99519.

Dr. Srinivasan's primary practice is Helen F Graham Cancer Center & Research Institute, at 200 Hygeia Dr, Newark, DE 19713 in New Castle County. The practice phone is (302) 623-4285.

Dr. Srinivasan's primary practice is Helen F Graham Cancer Center & Research Institute in Newark, Delaware. Dr. Srinivasan is also affiliated with Christiana Hospital. The medical group on file is ChristianaCare. Dmand AI also links Dr. Srinivasan to 4 more hospitals, 5 medical groups and 3 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Srinivasan practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Srinivasan's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Srinivasan is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Srinivasan's licenses on file in 6 states: Florida, South Dakota, Delaware, Pennsylvania, Georgia and Michigan.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Srinivasan treats.

CMS data shows 682 Medicare services from Dr. Srinivasan across 9 procedure codes in 2024, for 415 Medicare patients. Medicare paid $62,803 for them.

CMS counts 415 Medicare patients who saw Dr. Srinivasan in 2024. The largest group is 75 to 84, with 191 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Srinivasan's median patient age at 71, with 55% women.

In 2024, Dr. Srinivasan wrote 956 Medicare Part D claims for 238 patients. 72% of them were for generic drugs. CMS names the drug for 684 of them, across 23 drugs with 11 or more claims each, at $2,638,563 in total drug cost. In 2023, CMS named 1,044 claims across 31 drugs.

Dr. Srinivasan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Srinivasan as offering telehealth.

Dmand AI links 19 papers to Dr. Srinivasan, published from 2008 to 2025. 2022 was the busiest year, with 3. The most frequent topics are Antineoplastic Agents, Antibodies, Monoclonal, Humanized and Cochlear Implants. Dr. Srinivasan has published most often in Int J Mol Sci. Dr. Srinivasan's most frequent co-authors are Asher A. Chanan-Khan, MD, Pooja Prem Advani, MD and Bhagirathbhai Ravjibhai Dholaria, MD.

Dmand AI links Dr. Srinivasan to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Carcinoma, Intraductal, Noninfiltrating and Breast Carcinoma In Situ.

CMS Open Payments shows 41 general payments to Dr. Srinivasan from 21 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 92% of the total. Novartis Pharmaceuticals Corporation paid the most, $155.

Dr. Srinivasan graduated from Stanley Medical College SMC in 1996. Dr. Srinivasan is a member of ASCO.

Dr. Srinivasan is in network with 11 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.